Download PDF
J Neurol Surg Rep 2014; 75(01): e154-e159
DOI: 10.1055/s-0034-1378152
Case Report
Georg Thieme Verlag KG Stuttgart · New York

Isolated Recurrence of Secondary CNS Lymphoma: Case Report and Literature Review

Peter DeRosa
1   Department of Neurological Surgery, The George Washington University, Washington, District of Columbia, United States
,
Justin M. Cappuzzo
2   School of Medical and Health Sciences, The George Washington University, Washington, District of Columbia, United States
,
Jonathan H. Sherman
1   Department of Neurological Surgery, The George Washington University, Washington, District of Columbia, United States
› Author Affiliations
Further Information

Publication History

10 September 2014

04 April 2014

Publication Date:
04 June 2014 (online)

Also available at
   Permissions and Reprints

Abstract

Isolated secondary central nervous system lymphoma (SCNSL) relapse is a rare disease. Consequently, standardized treatment regimens have yet to be developed. We present an interesting case of isolated SCNSL presenting with altered mental status and panhypopituitarism in a patient at low risk of developing the disease. We also review the related literature and discuss newer, more aggressive treatments for primary CNS lymphoma and SCNSL.

Keywords

secondary central nervous system lymphoma - isolated - relapse - recurrence - aggressive treatment regimen
 

  • References

  • 1 Jellinger K, Radiaszkiewicz T. Involvement of the central nervous system in malignant lymphomas. Virchows Arch A Pathol Anat Histol 1976; 370 (4) 345-362
    CrossrefPubMedGoogle Scholar
  • 2 Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y. Secondary central nervous system lymphoma. Int J Hematol 2006; 84 (2) 128-135
    CrossrefPubMedGoogle Scholar
  • 3 Feugier P, Virion JM, Tilly H , et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 2004; 15 (1) 129-133
    CrossrefPubMedGoogle Scholar
  • 4 Kawano N, Ochiai H, Yoshida S , et al. Clinical features and treatment outcomes of isolated secondary central nervous system lymphomas in Miyazaki Prefecture. Int J Clin Oncol 2012; 17 (4) 336-340
    CrossrefPubMedGoogle Scholar
  • 5 Kim UR, Shah AD, Arora V, Solanki U. Isolated optic nerve infiltration in systemic lymphoma—a case report and review of literature. Ophthal Plast Reconstr Surg 2010; 26 (4) 291-293
    CrossrefPubMedGoogle Scholar
  • 6 Patrij K, Reiser M, Wätzel L , et al; International Primary CNS Lymphoma Collaborative Group (IPCG). Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis. Ger Med Sci 2011; 9: Doc11
    PubMedGoogle Scholar
  • 7 Stuplich M, Mayer K, Kim Y , et al. Richter syndrome and brain involvement: low-grade lymphoma relapsing as cerebral high-grade lymphoma. Acta Haematol 2012; 127 (2) 93-95
    CrossrefPubMedGoogle Scholar
  • 8 van Besien K, Gisselbrecht C, Pfreundschuh M, Zucca E. Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment. Leuk Lymphoma 2008; 49 (Suppl. 01) 52-58
    CrossrefPubMedGoogle Scholar
  • 9 Roth P, Stupp R, Eisele G, Weller M. Treatment of primary CNS lymphoma. Curr Treat Options Neurol 2014; 16 (1) 277
    CrossrefPubMedGoogle Scholar
  • 10 Prodduturi P, Bierman PJ. Current and emerging pharmacotherapies for primary CNS lymphoma. Clin Med Insights Oncol 2012; 6: 219-231
    PubMedGoogle Scholar
  • 11 Prica A, Chan K, Cheung MC. Combined modality therapy versus chemotherapy alone as an induction regimen for primary central nervous system lymphoma: a decision analysis. Br J Haematol 2012; 158 (5) 600-607
    CrossrefPubMedGoogle Scholar
  • 12 Thiel E, Korfel A, Hinkelbein W. Primary CNS lymphoma: chemotherapy followed by radiotherapy or chemotherapy alone? A randomized multicentric study. Front Radiat Ther Oncol 1999; 33: 349-353
    PubMedGoogle Scholar
  • 13 Freilich RJ, Delattre JY, Monjour A, DeAngelis LM. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 1996; 46 (2) 435-439
    CrossrefPubMedGoogle Scholar
  • 14 Citterio G, Ferreri AJ, Reni M. Current uses of radiation therapy in patients with primary CNS lymphoma. Expert Rev Anticancer Ther 2013; 13 (11) 1327-1337
    CrossrefPubMedGoogle Scholar
  • 15 Chamberlain MC. Treatment of primary CNS lymphoma (PCNSL) following successful treatment of systemic non-Hodgkin's lymphoma (NHL): a case series. J Neurooncol 2013; 113 (1) 27-32
    CrossrefPubMedGoogle Scholar
  • 16 Rubenstein JL, Gupta NK, Mannis GN, Lamarre AK, Treseler P. How I treat CNS lymphomas. Blood 2013; 122 (14) 2318-2330
    CrossrefPubMedGoogle Scholar
  • 17 Weller M, Martus P, Roth P, Thiel E, Korfel A ; German PCNSL Study Group. Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro-oncol 2012; 14 (12) 1481-1484
    PubMedGoogle Scholar
  • 18 Hiraga S, Arita N, Ohnishi T , et al. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg 1999; 91 (2) 221-230
    CrossrefPubMedGoogle Scholar
  • 19 Joerger M, Huitema AD, Krähenbühl S , et al. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer 2010; 102 (4) 673-677
    CrossrefPubMedGoogle Scholar
  • 20 Neuwelt EA, Goldman DL, Dahlborg SA , et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 1991; 9 (9) 1580-1590
    PubMedGoogle Scholar
  • 21 Angelov L, Doolittle ND, Kraemer DF , et al. Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J Clin Oncol 2009; 27 (21) 3503-3509
    CrossrefPubMedGoogle Scholar
  • 22 Khan RB, Shi W, Thaler HT, DeAngelis LM, Abrey LE. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?. J Neurooncol 2002; 58 (2) 175-178
    CrossrefPubMedGoogle Scholar
  • 23 Ferreri AJ, Reni M, Pasini F , et al. A multicenter study of treatment of primary CNS lymphoma. Neurology 2002; 58 (10) 1513-1520
    CrossrefPubMedGoogle Scholar
  • 24 Boehme V, Zeynalova S, Kloess M , et al; German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2007; 18 (1) 149-157
    CrossrefPubMedGoogle Scholar
  • 25 Bashir RM, Bierman PJ, Vose JM, Weisenburger DD, Armitage JO. Central nervous system involvement in patients with diffuse aggressive non-Hodgkin's lymphoma. Am J Clin Oncol 1991; 14 (6) 478-482
    CrossrefPubMedGoogle Scholar
  • 26 Tomita N, Kodama F, Sakai R , et al. Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations. Leuk Lymphoma 2000; 38 (3-4) 335-343
    CrossrefPubMedGoogle Scholar
  • 27 Wolf MM, Olver IN, Ding JC, Cooper IA, Liew KH, Madigan JP. Non-Hodgkin's lymphoma involving the central nervous system. Aust N Z J Med 1985; 15 (1) 16-21
    CrossrefPubMedGoogle Scholar
  • 28 van Besien K, Ha CS, Murphy S , et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998; 91 (4) 1178-1184
    PubMedGoogle Scholar
  • 29 Zinzani PL, Magagnoli M, Frezza G , et al. Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience. Leuk Lymphoma 1999; 32 (5–6) 571-576
    PubMedGoogle Scholar
  • 30 Kridel R, Dietrich PY. Prevention of CNS relapse in diffuse large B-cell lymphoma. Lancet Oncol 2011; 12 (13) 1258-1266
    CrossrefPubMedGoogle Scholar
  • 31 Roth P, Martus P, Kiewe P , et al. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial. Neurology 2012; 79 (9) 890-896
    CrossrefPubMedGoogle Scholar
  • 32 Fritsch K, Kasenda B, Hader C , et al. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann Oncol 2011; 22 (9) 2080-2085
    CrossrefPubMedGoogle Scholar
  • 33 Illerhaus G, Marks R, Müller F , et al. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol 2009; 20 (2) 319-325
    PubMedGoogle Scholar
  • 34 Kasenda B, Schorb E, Fritsch K, Finke J, Illerhaus G. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma—a long-term follow-up study. Ann Oncol 2012; 23 (10) 2670-2675
    CrossrefPubMedGoogle Scholar
  • 35 Kurzwelly D, Glas M, Roth P , et al. Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. J Neurooncol 2010; 97 (3) 389-392
    CrossrefPubMedGoogle Scholar
  • 36 Colocci N, Glantz M, Recht L. Prevention and treatment of central nervous system involvement by non-Hodgkin's lymphoma: a review of the literature. Semin Neurol 2004; 24 (4) 395-404
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Hegde U, Filie A, Little RF , et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 2005; 105 (2) 496-502
    CrossrefPubMedGoogle Scholar
  • 38 Spectre G, Gural A, Amir G, Lossos A, Siegal T, Paltiel O. Central nervous system involvement in indolent lymphomas. Ann Oncol 2005; 16 (3) 450-454
    CrossrefPubMedGoogle Scholar
  • 39 MacKintosh FR, Colby TV, Podolsky WJ , et al. Central nervous system involvement in non-Hodgkin's lymphoma: an analysis of 105 cases. Cancer 1982; 49 (3) 586-595
    CrossrefPubMedGoogle Scholar
  • 40 Gleissner B, Siehl J, Korfel A, Reinhardt R, Thiel E. CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology 2002; 58 (3) 390-396
    CrossrefPubMedGoogle Scholar
  • 41 Go JL, Lee SC, Kim PE. Imaging of primary central nervous system lymphoma. Neurosurg Focus 2006; 21 (5) E4
    PubMedGoogle Scholar
  • 42 Haldorsen IS, Espeland A, Larsson EM. Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. AJNR Am J Neuroradiol 2011; 32 (6) 984-992
    CrossrefPubMedGoogle Scholar
  • 43 Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009; 113 (17) 3896-3902
    CrossrefPubMedGoogle Scholar
  • 44 Kim SJ, Oh SY, Kim JS , et al. Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma. Ann Hematol 2011; 90 (5) 539-546
    CrossrefPubMedGoogle Scholar